Targeting interleukin-33 and thymic stromal lymphopoietin pathways for novel pulmonary therapeutics in asthma and COPD

胸腺基质淋巴细胞生成素 医学 免疫学 慢性阻塞性肺病 哮喘 先天性淋巴细胞 恶化 人口 临床试验 炎症 免疫系统 获得性免疫系统 内科学 环境卫生
作者
Ariel A. Calderon,Colin Dimond,David F. Choy,Rajita Pappu,Michele A. Grimbaldeston,Divya Mohan,Kian Fan Chung
出处
期刊:European Respiratory Review [European Respiratory Society]
卷期号:32 (167): 220144-220144 被引量:158
标识
DOI:10.1183/16000617.0144-2022
摘要

Interleukin-33 (IL-33) and thymic stromal lymphopoietin (TSLP) are alarmins that are released upon airway epithelial injury from insults such as viruses and cigarette smoke, and play critical roles in the activation of immune cell populations such as mast cells, eosinophils and group 2 innate lymphoid cells. Both cytokines were previously understood to primarily drive type 2 (T2) inflammation, but there is emerging evidence for a role for these alarmins to additionally mediate non-T2 inflammation, with recent clinical trial data in asthma and COPD cohorts with non-T2 inflammation providing support. Currently available treatments for both COPD and asthma provide symptomatic relief with disease control, improving lung function and reducing exacerbation rates; however, there still remains an unmet need for further improving lung function and reducing exacerbations, particularly for those not responsive to currently available treatments. The epithelial cytokines/alarmins are involved in exacerbations; biologics targeting TSLP and IL-33 have been shown to reduce exacerbations in moderate-to-severe asthma, either in a broad population or in specific subgroups, respectively. For COPD, while there is clinical evidence for IL-33 blockade impacting exacerbations in COPD, clinical data from anti-TSLP therapies is awaited. Clinical data to date support an acceptable safety profile for patients with airway diseases for both anti-IL-33 and anti-TSLP antibodies in development. We examine the roles of IL-33 and TSLP, their potential use as drug targets, and the evidence for target patient populations for COPD and asthma, together with ongoing and future trials focused on these targets.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
刚刚
香蕉觅云的应助被正直未来采纳,获得10
1秒前
阿努比斯的应助被lsw采纳,获得30
1秒前
老六发布了新的文献求助10
1秒前
2秒前
李金桥完成签到 ,获得积分10
2秒前
BAEKHYUNLUCKY发布了新的文献求助10
3秒前
3秒前
jefeer完成签到,获得积分10
4秒前
今后的应助被要减肥的朋友采纳,获得10
4秒前
5秒前
AA发布了新的文献求助10
5秒前
荼蘼发布了新的文献求助30
5秒前
Yangqx007完成签到,获得积分10
5秒前
jasmine970000发布了新的文献求助200
5秒前
6秒前
罗小黑发布了新的文献求助10
7秒前
8秒前
汉堡包的应助被喵喵拳采纳,获得10
9秒前
秋风的应助被YU采纳,获得10
9秒前
zzh完成签到,获得积分20
9秒前
皮蛋发布了新的文献求助10
11秒前
生动万言发布了新的文献求助10
11秒前
13秒前
无花果的应助被科研通管家采纳,获得10
15秒前
uTwTu的应助被科研通管家采纳,获得10
15秒前
打打的应助被科研通管家采纳,获得10
15秒前
15秒前
CodeCraft的应助被科研通管家采纳,获得10
15秒前
完美世界的应助被科研通管家采纳,获得10
15秒前
bkagyin的应助被科研通管家采纳,获得10
15秒前
华仔的应助被科研通管家采纳,获得10
16秒前
斯文败类的应助被科研通管家采纳,获得10
16秒前
16秒前
zouxinxin完成签到,获得积分10
17秒前
wangying完成签到 ,获得积分10
17秒前
张大旺完成签到,获得积分10
17秒前
12发布了新的文献求助10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175157
求助须知:如何正确求助?哪些是违规求助? 9566975
关于积分的说明 21789458
捐赠科研通 7769647
什么是DOI,文献DOI怎么找? 3431836
关于科研通互助平台的介绍 2556078
邀请新用户注册赠送积分活动 2477241